A Novel CD7 Chimeric Antigen Receptor-modified NK-92MI Cell Line Targeting T-cell Acute Lymphoblastic Leukemia
Overview
Authors
Affiliations
Chimeric antigen receptor (CAR) immunotherapy has recently shown promise in clinical trials for B-cell malignancies; however, designing CARs for T-cell based diseases remain a challenge since most target antigens are shared between normal and malignant cells, leading to CAR-T cell fratricide. CD7 is highly expressed in T-cell acute lymphoblastic leukemia (T-ALL), but it is not expressed in one small group of normal T lymphocytes. Here, we constructed monovalent CD7-CAR-NK-92MI and bivalent dCD7-CAR-NK-92MI cells using the CD7 nanobody VHH6 sequences from our laboratory. Both CD7-CAR-NK-92MI and dCD7-CAR-NK-92MI cells consistently showed specific and potent anti-tumor activity against T-cell leukemia cell lines and primary tumor cells. We observed robust cytotoxicity of the bivalent mdCD7-CAR-NK-92MI monoclonal cells against primary T-ALL samples. In agreement with the enhanced cytotoxicity of mdCD7-CAR-NK-92MI cells, significant elevations in the secretion of Granzyme B and interferon γ (IFN-γ) were also found in mdCD7-CAR-NK-92MI cells in response to CD7-positive primary T-ALL cells compared with NK-92MI-mock cells. Furthermore, we also demonstrated that mdCD7-CAR-NK-92MI cells significantly inhibited disease progression in xenograft mouse models of T-ALL primary tumor cells. Our data suggest that CD7-CAR-NK-92MI cells can be used as a new method or a complementary therapy for treating T-cell acute lymphocytic leukemia.
CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models.
Zhi L, Zhang Z, Gao Q, Shang C, He W, Wang Y BMC Cancer. 2025; 25(1):337.
PMID: 40000974 PMC: 11853679. DOI: 10.1186/s12885-025-13780-2.
Gierschek F, Schlueter J, Kuhnel I, Feigl F, Schmiedel D, Prufer M Transfus Med Hemother. 2025; 52(1):42-60.
PMID: 39944413 PMC: 11813277. DOI: 10.1159/000540962.
Lajevardi M, Ashrafpour M, Mubarak S, Rafieyan B, Kiani A, Noori E Med Oncol. 2024; 42(1):11.
PMID: 39572459 PMC: 11582151. DOI: 10.1007/s12032-024-02547-7.
Andrea A, Chiron A, Sarrabayrouse G, Bessoles S, Hacein-Bey-Abina S Front Immunol. 2024; 15:1459818.
PMID: 39430751 PMC: 11486669. DOI: 10.3389/fimmu.2024.1459818.
Zhou S, Yang Y, Jing Y, Zhu X Front Immunol. 2024; 15:1435635.
PMID: 39372412 PMC: 11449748. DOI: 10.3389/fimmu.2024.1435635.